Spyre Therapeutics, Inc. SYRE Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax)?
- Spyre Therapeutics, Inc. (SYRE) reported unrealized losses on investments (before tax) of $1.06M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax) increased by 556.5% year-over-year, from $161K to $1.06M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax)?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s unrealized losses on investments (before tax) has grown at a 55.3% compound annual growth rate (CAGR), from $31K to $116K.